WO2007020349A1 - Émulsion de type huile-dans-eau pour application topique en dermatologie - Google Patents
Émulsion de type huile-dans-eau pour application topique en dermatologie Download PDFInfo
- Publication number
- WO2007020349A1 WO2007020349A1 PCT/FR2006/001930 FR2006001930W WO2007020349A1 WO 2007020349 A1 WO2007020349 A1 WO 2007020349A1 FR 2006001930 W FR2006001930 W FR 2006001930W WO 2007020349 A1 WO2007020349 A1 WO 2007020349A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion according
- weight
- water
- emulsion
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- Oil-in-water emulsion for topical application in dermatology Oil-in-water emulsion for topical application in dermatology
- the present invention relates to a novel topical composition in the form of an oil-in-water emulsion, with a high proportion of oily phase in the internal phase of the emulsion, combining the occlusive and emollient properties of an ointment without having the disadvantages of greasy feel, while promoting the therapeutic properties of the biologically active agent present in said composition.
- the use of an ointment is widely preferred.
- the ointment is mainly composed of fatty substances that bring emollience to the skin and limit desquamation.
- this dosage form has the disadvantage, by its nature, to have a greasy and sticky touch, resulting in discomfort for the patient's everyday life (unpleasant sensations, greasy spots on clothes, etc.).
- these ointments are based on a high percentage of petrolatum.
- compositions for topical application to the skin in which the fatty phase represents from 60% to 70% by weight.
- aqueous continuous phase emulsions which offer the advantage of a non-greasy touch, a great ease of spreading, etc.
- the emollient power of such emulsions is very often insufficient or even unsatisfactory.
- compositions having both the benefits of ointments (occlusivity, emollience) and emulsions in aqueous continuous phase (non-greasy feel, cosmetically acceptable, ease of spreading, no residues), while avoiding disadvantages related to these two types of formulation.
- compositions should promote the therapeutic properties of the biologically active agent, to ensure its effectiveness in this new dosage form.
- these compositions should have bioequivalence in terms of vasoconstriction with major products on the market, especially for topical compositions containing corticosteroids.
- the inventors have now discovered a new emulsion of oil-in-water type, containing a very high proportion of fat phase, corresponding to the proportions generally encountered in water-in-oil type emulsions.
- This new emulsion also called lipocreme, could be obtained using an oil-in-water type nonionic emulsifier system combined with one or more propenetrating agents.
- the aqueous continuous phase emulsion according to the invention has the advantage of a non-greasy feel while providing satisfactory emollient power brought by the high percentage of fat phase.
- this new formulation has a therapeutic activity equivalent to that expected in the case of ointments with a high concentration of petrolatum.
- the present invention relates first of all to an oil-in-water type emulsion containing at least one therapeutic agent for topical application and further comprising: a) from 25% to 60% by weight of a fatty phase; b) from 1% to 15% by weight of a nonionic emulsifier system; c) from 1% to 30% by weight of at least one propenetrating agent; and d) from 5% to 50% by weight of water.
- the emulsion according to the present invention comprises a quantity of fat phase of between 35% and 50% by weight.
- fatty phase is understood to mean one or more compounds chosen from emollients, waxes and fatty alcohols, alone or as mixtures of two or more of them.
- the emollients will advantageously be the emollients commonly used for the formulations referred to in the present invention and well known to those skilled in the art.
- vegetable oils such as cottonseed oil, or almond oil
- esters such as isopropyl palmitate, and isopropyl myristate
- mineral oils such as light mineral oils, volatile or non-volatile silicone oils, for example dimethicone and cyclomethicone
- petrolatum such as light mineral oils, volatile or non-volatile silicone oils, for example dimethicone and cyclomethicone.
- the waxes which can also be used as constituents of the emulsion fatty phase according to the present invention are the waxes commonly used by those skilled in the art in this field, among which, for example, beeswax can be mentioned, carnauba wax, ozokerite, paraffin and dimethiconol behenate.
- the fatty phase may contain one or more fatty alcohols known to those skilled in the art, and as such, there may be mentioned in particular, and not limited to, cetyl alcohol and stearyl alcohol.
- the fatty phase will preferably contain one or more of the following ingredients: isopropyl palmitate, a mineral oil, petrolatum, dimethicone.
- the fatty phase is emulsified by means of a nonionic emulsifying system.
- HLB hydrophilic-lipophilic balance
- ionic anionic, cationic, amphoteric
- nonionic Nonionic surfactants are surfactants that do not dissociate into ions in water and are therefore insensitive to pH changes.
- Nonionic surfactants are particularly well suited for the preparation of the oil-in-water type emulsion, object of the present invention.
- the emulsifying system, component of the emulsion of the invention comprises at least one nonionic surfactant, hydrophilic predominant fraction, that is to say having a high HLB, greater than about 10.
- said high HLB nonionic surfactants have an HLB between 10 and 18.
- low HLB nonionic surfactants examples include sorbitan esters, such as sorbitan monostearate (sold as Span 60 by Unichema), glycerol esters (sold under the name Cutina GMSVPH by Cognis). ) such as glycerol monostearate (Cutina GMS from Cognis), low HLB sucrose esters such as sucrose distearate.
- said nonionic surfactants exhibiting low HLB have an HLB of less than 10.
- the nonionic surfactants may be used alone or in a mixture of two or more of them to form the emulsifying system comprising the emulsion of the invention.
- one or more pairs of "high HLB nonionic surfactant” / "low HLB nonionic surfactant” will be used as the emulsifying system. It may in particular be a nonionic emulsifying system comprising at least one nonionic surfactant having an HLB greater than about 10 and at least one nonionic surfactant having an HLB of less than about 10.
- the emulsifying system is composed of the glycerol monostearate / ceteareth 20 surfactant couple.
- the ratio of each of the two surfactants forming the aforementioned pair is most often determined by the calculation of the required HLB of the fat phase used.
- the search for the optimal emulsification of a fat or a mixture of fat passes through the preliminary determination of its required HLB. Indeed, each fat has a defined required HLB. We can not operate in all cases with the same emulsifier.
- the HLB required by the fat phase corresponds to the HLB value of the emulsifier or the pair of emulsifiers that will provide the most stable emulsion with the fatty substances considered.
- the emulsion of the present invention comprises one or more propenetrating agents in preferential concentrations ranging from 1 to 30%, preferably from 5% to 25%, and more preferably ranging from 15%. at 20% by weight relative to the total weight of the composition.
- the propenetrating agents must generally be non-solubilizing therapeutic agents at the percentage used, not cause harmful exothermic reactions for the various components, help the good dispersion of said therapeutic agents and have anti-foam properties.
- the pro-penetrating agents are preferably used, without this list being limiting, of compounds selected from those known to those skilled in the art, such as propylene glycol, dipropylene glycol, Transcutol ® (ethoxydiglycol), propylene glycol dipelargonate glycol, lauroglycol, urea, acetone, oleic acid.
- Propenetrating agents may be well understood in mixtures of two or more of them.
- the propenetrating agent is chosen from propylene glycol, dipropylene glycol and propylene glycol dipelargonate. More preferably, the propenetrating agent is propylene glycol.
- propenetrating agent will depend on the nature of the therapeutic agent included in the emulsion of the invention.
- the aqueous phase of the emulsion according to the invention comprises water, purified or not, demineralized or not, and in particular a floral water such as cornflower water, or a natural thermal or mineral water, for example chosen among the water of Vittel, the waters of the Vichy basin, the water of Uriage, the water of the Roche-Posay, the water of the Bourboule, the water of Enghien-les-Bains, the water of Saint Gervais-les-Bains, the water of Neris-Bains, the water of Allevard-les-Bains, the water of Digne, the water of Maizines, the water of Neyrac-les- Baths, the water of Lons-le-Saunier, the Eaux Bonnes, the water of Rochefort, the water of Saint Christau, the water of the Fumades and the water of Tercis-les-Bains, the water of Avène or the water of Aix les Bains.
- a floral water such as cornflower water
- the emulsion according to the present invention comprises a substantial amount of water, of between 5% and 50%, advantageously about 30% by weight. emulsion.
- the oil-in-water emulsion of the present invention is particularly suitable for the treatment and / or prevention of skin diseases.
- the therapeutic agent included in said emulsion will therefore preferably be a therapeutically active compound in the treatment and / or prevention of this type of disease.
- the emulsions of the present invention have proved particularly effective for the topical application to the skin of therapeutic agents of the class of corticosteroids, already known and marketed.
- the therapeutic agents of the corticosteroid class will be chosen from clobetasol 17-propionate, desonide, betamethasone, betamethasone acetate, betamethasone valerate, betamethasone dipropionate and dipropionate monohydrate.
- betamethasone the diflucortolone valerate, fluticasone valerate, 17-butyrate hydrocortisone, mometasone fuorate, halobetasol propionate, desoximetasone, clobetasone butyrate, hydrocortisone, cortisone, prednisolone, miconazole, prednisone, triamcinolone acetonide, methylprednisolone, fluometholone, fluocinolone acetonide, desonide.la dexamethasone, dexamethasone dipropionate, aclasone, dexamethasone 17, 21 -dipropionate, mometasone furoate, diflorasone diacetate, or mixtures thereof.
- the therapeutic agents of the class of corticosteroids will preferably be chosen from clobetasol 17-propionate, desonide and betamethasone valerate, clobetasol 17-propionate being the preferred therapeutic agent.
- the emulsions of the present invention can also be used for formulations for cutaneous topical applications of vitamin D and its analogs.
- vitamin D analogs By way of non-limiting example of vitamin D analogs, mention may be made of ergocalciferol, alfacalcidol, calcifediol, calcipotriol, calcitriol, cholecalciferol, tacalcitol, 6- (3-hydroxy acid). -5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylselanyl) -nicotinic acid, 4- [6-ethyl-4 '- (1-ethyl-1-hydroxy) propyl) -2'-propyl-biphenyl-3-loxymethyl] -2-hydroxymethyl-phenyl ⁇ -methanol, or mixtures thereof.
- the emulsions of the present invention may also be used for formulations for topical cutaneous applications of retinoids.
- Retinoid means any compound binding to the RAR and / or RXR receptors.
- the retinoid is a compound chosen from the family of benzonaphthalene retinoids as described in the patent application EP 0 199 636.
- adapalene (6- [3- (1-adamantyl) acid) is preferred.
- 4-methoxyphenyl] -2-naphthhanoic as well as its precursors and / or derivatives.
- Tretinoin and isotretinoin can also be used.
- retinoid precursors are meant their immediate biological precursors or substrates, as well as their chemical precursors.
- Derivatives of retinoids include both their metabolic derivatives and their chemical derivatives.
- retinoids can be chosen from those described in the following patents or patent applications: 118 4,666,941, US 4,581,380, EP 0 210 929,
- EP 0 823 903 EP 0 832 057, EP 0 832 081, EP 0 816 352, EP 0 826 657,
- oil-in-water emulsion of the present invention may be made with a combination of different therapeutic agents selected from the different categories defined above.
- One of the main objectives of the invention is to provide a system for topical application having the advantages of a fat cream, with regard to the properties of penetration through the epidermis, as well as the advantages of an aqueous emulsion, from the point of view of comfort and ease of use, as well as the stability of said formulation.
- the emulsion described here and object of the present invention may further comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestering agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants conventional, inorganic or organic pH buffers, dyes, bases or acids, perfumes, essential oils, cosmetic active agents, moisturizers, vitamins, sphingolipids, self-tanning compounds, such as DHA, gelling agents, soothing and skin-protecting agents such as Pallantoin.
- any additive usually used in the cosmetic or pharmaceutical field such as sequestering agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants conventional, inorganic or organic pH buffers, dyes, bases or acids, perfumes, essential oils, cosmetic active agents, moisturizers, vitamins, sphingolipids, self-tanning compounds, such as DHA, gelling agents, soothing and skin-protecting agents such as Pallantoin.
- EDTA ethylenediamine tetracetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinyl urea, parabens, or mixtures thereof.
- antioxidants mention may be made, by way of nonlimiting examples, of ascorbic acid and its salts, tocopherols and sulphite salts, such as sodium metabisulphite, sodium sulphite, butylhydroxyanisole, beta-butylhydroxytoluene and propyl gallate,
- the oxidizing agent is selected from DL-alpha tocopherol, butylhydroxyanisole, butylhydroxytoluene and propyl gallate.
- humectants examples include glycerin and sorbitol, and as pH buffers, citric acid and sodium citrate.
- the emulsion according to the invention may also contain, as additive, one or more compounds falling within the category of gelling agents, that is to say capable of conferring a sufficient viscosity on the emulsion to maintain the suspension in suspension. various components of said emulsion.
- gelling agents may advantageously be chosen from the gelling agents currently used, and especially chosen from, by way of non-limiting examples, among carbomer, hydroxyethylcellulose, methylcellulose, guar gum, xanthan gum, hectorite, pectin, magnesium aluminum silicate, gelling agents of the family of polyacrylamides such as the mixture sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 sold under the name Simulgel 600 ® by the company SEPPIC, the polyacrylamide / isoparaffin C13 14 / laureth-7 as, for example, the one sold under the name Sepigel 305 ® by Seppic, the family of acrylic polymers coupled to hydrophobic chains, such as the copolymer PEG-150 / decyl / SMDI sold under the name Aculyn 44 ® (polycondensate comprising at least, as components, a polyethylene glycol containing 150 or 180 mol of
- the preferred gelling agents are xanthan gum, magnesium aluminum silicate (Vanderbilt Veegum K), magnesium silicate and aluminum / aluminum / Titanium Dioxide (Vanderbilt Veegum ULTRA) or mixtures thereof.
- the oil-in-water emulsion of the present invention comprises: a. from 35% to 45% by weight of a fatty phase; b. from 5% to 15% by weight of a nonionic emulsifier system; vs. from 15% to 20% by weight of at least one propenetrating agent; d. from 0.01% to 0.5% by weight of at least one therapeutic agent; e. from 5% to 50% by weight of water; and F. additives, preferably between 0.2% to 25% by weight.
- the present invention relates to a process for preparing the oil-in-water type emulsion as defined above, characterized in that it comprises the steps of: a. dissolution and / or dispersion in water, with stirring, of at least one pro-penetrating agent and the optional additive (s), at a temperature of between 60 ° C. and 95 ° C., until a phase is obtained homogeneous aqueous; b. incorporation, with stirring, of the aqueous phase in the fatty phase, in which the pair of emulsifiers, previously heated to a temperature of between 60 ° C. and 95 ° C., has been solubilized; and vs. incorporation, with stirring and at a temperature below 4O 0 C, of the therapeutic agent, may be dissolved beforehand in a suitable solvent.
- solvent any solvent capable of solubilizing the therapeutic agent (s), and / or of dissolving the therapeutic agent (s), when these are in solid form, in order to allow their perfect incorporation into the fatty phase emulsion. aqueous phase.
- the present invention relates to a physiologically acceptable galenic formulation which is compatible with topical application to the skin, superficial body growths or mucous membranes, comprising at least one oil-in-water type emulsion, as it comes from to be defined in this presentation.
- the dosage form is an oil-in-water emulsion itself.
- the invention also relates to the use of the emulsion described above or the aforementioned formulation for application to the skin, superficial body growths or mucous membranes of at least one therapeutic agent belonging to the class of corticosteroids, in particular in view of their use for the prevention and / or treatment of dermatological diseases.
- Said therapeutic agents are particularly suitable in the following treatment areas:
- the oil-in-water emulsion of the present invention has proved to be entirely suitable for the prevention and treatment of all forms of psoriasis, whether cutaneous, mucous or ungual. .
- the fat phase is weighed in a receiving beaker which is then placed in a waterbath at 78 ° C.
- the aqueous phase is weighed in a beaker and then the citric acid is added.
- the sodium citrate is then dispersed with vigorous stirring.
- the gelling agents are then added and, after homogenization, propylene glycol, by heating at 78 ° C. with Rayneri stirring.
- the hot fatty phase is then stirred Rayneri.
- the aqueous phase is poured into the fatty phase with stirring (1000 rpm) and heating at 78 ° C for 10 min. It is left stirring (1000 rpm), without heating.
- the therapeutic agent is prepared by adding it, under magnetic stirring, in a beaker, to propylene glycol, until complete dissolution.
- This active phase is then incorporated into the emulsion, below 40 ° C.
- the macroscopic observation makes it possible to guarantee the physical integrity of the products and the microscopic observation makes it possible to verify that there is no recrystallization of the solubilized active ingredient and no significant evolution of the size of the blood cells of the emulsion.
- a HAAKE ® rheometer VT500 type with a measurement mobile SVDIN is used.
- the rheograms were performed at 25 0 C by varying the shear rate over time, and measuring the stress.
- flow threshold (tau 0) is meant the force required (minimum shear stress) to overcome Van der Waals cohesive forces and cause flow.
- the flow threshold is equivalent to the value found at 4 s -1 .
- Chemical stability is an assay, by HPLC, of the active and preservatives at room temperature (Ta) and at 45 ° C.
- This formulation is in accordance with the object of the present invention: no recrystallization of the therapeutic agent was observed after 3 months at 4 ° C.
- the evaluation tests are carried out on the formulations 2, 3 and 4 of Examples 3, 4 and 5, and, for comparison with the commercial products Temovate Cream ® and Temovate Emollient Cream ® .
- the study was conducted on 7 healthy subjects, male or female, aged 18 to 70 years.
- the study is carried out over 2 days. The three formulations and the two reference products were applied to each volunteer.
- An area not receiving product served as a control area.
- the obtained variables were subjected to a variant analysis and each formulation was compared to the untreated site and the reference product at each measurement time.
- Temovate Cream ® induces the most important whitening. Statistically, 1 AUC of Temovate Cream ® is significantly different from the AUC of the untreated zone and formulation 2 of Example 3 for the parameter a *. For parameter L *, the AUC of Temovate Cream ® is significantly different from the AUC all other test areas, except those treated with Temovate Emollient Cream ® .
- Temovate Emollient Cream ® Temovate Emollient Cream ®
- formulation 3 of Example 4 formulation 2 of Example 3 are quite close to each other.
- the AUCs of these 3 products are all significantly different from the 1 AUC of the untreated zone for parameter a *.
- parameter L * only the AUC of the Formulation of Example 3 is not different from the untreated zone.
- the AUC of formulation 2 of Example 3 appears to be the weakest for both the parameter a * and the parameter L *. Statistically, I 1 AUC of the latter appears as significantly different from the untreated zone for the parameter a * but not for the parameter L *.
- Student's t-test was performed with a significance threshold of less than 0.1.
- This test evaluates the irritating potential of Formulation 2 and Formulation 3 in various irritation tests in healthy volunteers.
- METHODOLOGY The study was conducted over 15 days for each volunteer. The volunteers presented themselves every day at the test center, except at D4, D8, D16, D11 and D12 where the applications were performed at home.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06794313A EP1915133A1 (fr) | 2005-08-11 | 2006-08-09 | Émulsion de type huile-dans-eau pour application topique en dermatologie |
JP2008525600A JP2009504619A (ja) | 2005-08-11 | 2006-08-09 | 皮膚科学における局所適用用水中油型エマルション |
CA002617963A CA2617963A1 (fr) | 2005-08-11 | 2006-08-09 | Emulsion de type huile-dans-eau pour application topique en dermatologie |
MX2008002012A MX2008002012A (es) | 2005-08-11 | 2006-08-09 | Emulsion de tipo aceite en agua para la aplicacion topica en dermatologia. |
BRPI0616520-6A BRPI0616520A2 (pt) | 2005-08-11 | 2006-08-09 | emulsão de tipo óleo-em-água, processo de preparação de uma emulsão e seu uso |
AU2006281346A AU2006281346B2 (en) | 2005-08-11 | 2006-08-09 | Oil-in-water-type emulsion for topical application in dermatology |
US12/068,670 US20080207570A1 (en) | 2005-08-11 | 2008-02-08 | Topically applicable oil-in-water emulsions and dermatological applications thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0508524A FR2889662B1 (fr) | 2005-08-11 | 2005-08-11 | Emulsion de type huile-dans-eau pour application topique en dermatologie |
FR0508524 | 2005-08-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/068,670 Continuation US20080207570A1 (en) | 2005-08-11 | 2008-02-08 | Topically applicable oil-in-water emulsions and dermatological applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007020349A1 true WO2007020349A1 (fr) | 2007-02-22 |
Family
ID=36273334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/001930 WO2007020349A1 (fr) | 2005-08-11 | 2006-08-09 | Émulsion de type huile-dans-eau pour application topique en dermatologie |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080207570A1 (fr) |
EP (1) | EP1915133A1 (fr) |
JP (1) | JP2009504619A (fr) |
KR (1) | KR20080033389A (fr) |
CN (1) | CN101304729A (fr) |
AU (1) | AU2006281346B2 (fr) |
BR (1) | BRPI0616520A2 (fr) |
CA (1) | CA2617963A1 (fr) |
FR (1) | FR2889662B1 (fr) |
MX (1) | MX2008002012A (fr) |
RU (2) | RU2008108973A (fr) |
WO (1) | WO2007020349A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526124A (ja) * | 2007-05-04 | 2010-07-29 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 皮膚疾患用および化粧用脱色素沈着組成物、その調製方法、およびその使用 |
WO2017037663A1 (fr) | 2015-09-02 | 2017-03-09 | Cadila Healthcare Limited | Compositions topiques comprenant des corticostéroïdes |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
NZ563560A (en) | 2005-06-01 | 2009-11-27 | Stiefel Res Australia Pty Ltd | Vitamin formulation for treating a dermatological skin disorder |
FR2892936A1 (fr) * | 2005-11-10 | 2007-05-11 | Galderma Res & Dev | Composition pharmaceutique ou cosmetique, et procede de solubilisation mixte pour preparer la composition. |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
FR2898499B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
FR2898498B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
EP2008651A1 (fr) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | Patch bioérodable |
US20100249060A1 (en) * | 2009-02-23 | 2010-09-30 | Smith Jan G | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
WO2010115164A1 (fr) * | 2009-04-03 | 2010-10-07 | Medicis Pharmaceutical Corporation | Compositions topiques |
JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
DK2473161T3 (en) | 2009-08-31 | 2017-09-11 | Dr Reddys Laboratories Ltd | TOPICAL FORMULATIONS INCLUDING A STEROID |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US20110212035A1 (en) * | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
ME02445B (fr) * | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Formulation topique pour inhibiteur de jak |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
AU2012228273B2 (en) | 2011-03-14 | 2015-08-20 | Drug Delivery Solutions Limited | An ophthalmic composition |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
JP5909941B2 (ja) * | 2011-09-08 | 2016-04-27 | 大正製薬株式会社 | ステロイド性抗炎症薬含有外用剤 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA3178452A1 (fr) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Formes galeniques a liberation prolongee du ruxolitinib |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
CA2908041C (fr) * | 2013-04-04 | 2018-05-01 | Hyundai Pharm Co., Ltd. | Composition pour preparation a usage externe dotee de permeabilite transdermique amelioree |
AR096459A1 (es) * | 2013-06-03 | 2015-12-30 | Tolmar Inc | Composiciones de corticosteroides y método de fabricación |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
US20160184431A1 (en) * | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
DE102014010875A1 (de) * | 2014-07-25 | 2016-01-28 | Basf Se | Transparente Textilpflegemittel |
RU2018119510A (ru) | 2015-10-30 | 2019-12-05 | Тимбер Фармасьютикалз ЭлЭлСи | Композиции изотретиноина и их применение и способы |
EP3641728B9 (fr) * | 2017-06-23 | 2021-06-30 | Laboratorios SALVAT, S.A. | Composition de clobétasol en nanoémulsion huile et eau |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (fr) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one) |
EP3542788A1 (fr) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Composition topique comprenant calcipotriol et dipropionate de bétaméthasone |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
CA3158619A1 (fr) * | 2019-11-01 | 2021-05-06 | Colgate-Palmolive Company | Compositions de soins personnels stables a faible ph et leurs procedes d'utilisation |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN113925800A (zh) * | 2021-11-03 | 2022-01-14 | 时垠(上海)生物科技有限公司 | 提高单硬脂酸甘油酯乳化体系乳化能力的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020852A1 (fr) * | 1996-11-12 | 1998-05-22 | Pharmacia & Upjohn Company | Compositions pharmaceutiques contenant de l'huile de noix de kukui |
US6403654B1 (en) * | 2000-04-13 | 2002-06-11 | Mariana De Oliveira | Compositions for and method of treatment for psoriasis |
US20030129208A1 (en) * | 2002-01-07 | 2003-07-10 | Alberts David S. | Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
WO2003097100A1 (fr) * | 2002-05-15 | 2003-11-27 | Engelbrecht, Edna | Composition topique de traitement d'etats inflammatoires de la peau |
US6699464B1 (en) * | 2001-07-30 | 2004-03-02 | Stiefel Laboratories, Inc. | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
JP3454385B2 (ja) * | 1993-10-15 | 2003-10-06 | 啓次郎 佐藤 | O/w型皮膚用クリームの製造方法 |
US5972993A (en) * | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
FR2787025B1 (fr) * | 1998-12-14 | 2002-10-11 | Oreal | Composition sous forme d'emulsion h/e a forte teneur en cire et ses utilisations dans les domaines cosmetique et dermatologique |
FR2833841B1 (fr) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
BRPI0408476A (pt) * | 2003-03-13 | 2006-04-04 | 3M Innovative Properties Co | métodos para melhorar a qualidade da pele |
KR101243526B1 (ko) * | 2004-08-31 | 2013-03-20 | 스티펠 리서치 오스트레일리아 피티와이 리미티드 | 마이크로에멀젼 및 서브마이크론 에멀젼 방법 및 조성물 |
-
2005
- 2005-08-11 FR FR0508524A patent/FR2889662B1/fr not_active Expired - Fee Related
-
2006
- 2006-08-09 JP JP2008525600A patent/JP2009504619A/ja active Pending
- 2006-08-09 BR BRPI0616520-6A patent/BRPI0616520A2/pt not_active IP Right Cessation
- 2006-08-09 CN CNA2006800374997A patent/CN101304729A/zh active Pending
- 2006-08-09 KR KR1020087003334A patent/KR20080033389A/ko not_active Application Discontinuation
- 2006-08-09 MX MX2008002012A patent/MX2008002012A/es active IP Right Grant
- 2006-08-09 AU AU2006281346A patent/AU2006281346B2/en not_active Expired - Fee Related
- 2006-08-09 RU RU2008108973/15A patent/RU2008108973A/ru unknown
- 2006-08-09 CA CA002617963A patent/CA2617963A1/fr not_active Abandoned
- 2006-08-09 EP EP06794313A patent/EP1915133A1/fr not_active Withdrawn
- 2006-08-09 WO PCT/FR2006/001930 patent/WO2007020349A1/fr active Application Filing
-
2008
- 2008-02-08 US US12/068,670 patent/US20080207570A1/en not_active Abandoned
-
2011
- 2011-06-21 RU RU2011125550/15A patent/RU2011125550A/ru not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020852A1 (fr) * | 1996-11-12 | 1998-05-22 | Pharmacia & Upjohn Company | Compositions pharmaceutiques contenant de l'huile de noix de kukui |
US6403654B1 (en) * | 2000-04-13 | 2002-06-11 | Mariana De Oliveira | Compositions for and method of treatment for psoriasis |
US6699464B1 (en) * | 2001-07-30 | 2004-03-02 | Stiefel Laboratories, Inc. | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
US20030129208A1 (en) * | 2002-01-07 | 2003-07-10 | Alberts David S. | Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
WO2003097100A1 (fr) * | 2002-05-15 | 2003-11-27 | Engelbrecht, Edna | Composition topique de traitement d'etats inflammatoires de la peau |
Non-Patent Citations (1)
Title |
---|
"Non-Prescription Treatments for Rosacea", 23 June 2004 (2004-06-23), pages 1 - 5, XP002384507, Retrieved from the Internet <URL:http://www.internationalrosaceafoundation.org/nonprescription.html> [retrieved on 20060607] * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526124A (ja) * | 2007-05-04 | 2010-07-29 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 皮膚疾患用および化粧用脱色素沈着組成物、その調製方法、およびその使用 |
WO2017037663A1 (fr) | 2015-09-02 | 2017-03-09 | Cadila Healthcare Limited | Compositions topiques comprenant des corticostéroïdes |
Also Published As
Publication number | Publication date |
---|---|
FR2889662A1 (fr) | 2007-02-16 |
JP2009504619A (ja) | 2009-02-05 |
US20080207570A1 (en) | 2008-08-28 |
AU2006281346A1 (en) | 2007-02-22 |
CA2617963A1 (fr) | 2007-02-22 |
KR20080033389A (ko) | 2008-04-16 |
FR2889662B1 (fr) | 2011-01-14 |
EP1915133A1 (fr) | 2008-04-30 |
RU2008108973A (ru) | 2009-09-20 |
RU2011125550A (ru) | 2012-12-27 |
MX2008002012A (es) | 2008-03-25 |
BRPI0616520A2 (pt) | 2011-06-21 |
AU2006281346B2 (en) | 2012-03-29 |
CN101304729A (zh) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007020349A1 (fr) | Émulsion de type huile-dans-eau pour application topique en dermatologie | |
CA2466321C (fr) | Gel comprenant au moins un retinoide et du peroxyde de benzoyle | |
EP3025763B1 (fr) | Gel creme comprenant au moins un retinoide et du peroxyde de benzoyle | |
EP2125117B1 (fr) | Emulsion comprenant au moins un retinoide et du péroxyde de benzoyle | |
CA2631123C (fr) | Composition sous forme de spray comprenant un corticoide et une phase huileuse | |
CA2670601A1 (fr) | Compositions sous forme d'onguent comprenant un derive de vitamine d | |
EP1758588A1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
CA2745457A1 (fr) | Composition pharmaceutique topique comprenant un principe actif sensible a l'eau | |
EP2240152B1 (fr) | Composition comprenant un retinoide et du peroxyde de benzoyle disperse | |
EP2872116B1 (fr) | Composition dermatologique comprenant des oléosomes et des rétinoïdes, son procédé de préparation et son utilisation | |
EP2029133B1 (fr) | Compositions comprenant au moins un dérivé de l'acide naphtoïque et au moins un agent filmogène, leurs procédés de préparation, et leurs utilisations | |
FR2894474A1 (fr) | Gel depigmentant hydroalcoolique | |
EP2173326A2 (fr) | Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680037499.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006794313 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006281346 Country of ref document: AU Ref document number: 2617963 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008525600 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/002012 Country of ref document: MX Ref document number: 1020087003334 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006281346 Country of ref document: AU Date of ref document: 20060809 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006281346 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008108973 Country of ref document: RU Ref document number: 2067/DELNP/2008 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006794313 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0616520 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080208 |